Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real world efficacy of dolutegravir plus lamivudine in people living with HIV with undetectable viral load after previous failures.
Gagliardini R, Lorenzini P, Cozzi-Lepri A, Tavelli A, Borghi V, Galli L, Tagliaferri G, Maggiolo F, Mussini C, Castagna A, Monforte AD, Antinori A. Gagliardini R, et al. J Glob Antimicrob Resist. 2023 Mar;32:158-163. doi: 10.1016/j.jgar.2022.11.010. Epub 2022 Nov 17. J Glob Antimicrob Resist. 2023. PMID: 36402369 Free article.
Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors.
De Luca A, Di Giambenedetto S, Lo Presti A, Sierra S, Prosperi M, Cella E, Giovanetti M, Torti C, Caudai C, Vicenti I, Saladini F, Almi P, Grima P, Blanc P, Fabbiani M, Rossetti B, Gagliardini R, Kaiser R, Ciccozzi M, Zazzi M. De Luca A, et al. Among authors: gagliardini r. Open Forum Infect Dis. 2015 Mar 31;2(2):ofv043. doi: 10.1093/ofid/ofv043. eCollection 2015 Apr. Open Forum Infect Dis. 2015. PMID: 26213689 Free PMC article.
Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort study.
Focà E, Fabbiani M, Prosperi M, Quiros Roldan E, Castelli F, Maggiolo F, Di Filippo E, Di Giambenedetto S, Gagliardini R, Saracino A, Di Pietro M, Gori A, Sighinolfi L, Pan A, Postorino MC, Torti C; Italian MASTER Cohort. Focà E, et al. Among authors: gagliardini r. Medicine (Baltimore). 2016 Jul;95(29):e4091. doi: 10.1097/MD.0000000000004091. Medicine (Baltimore). 2016. PMID: 27442636 Free PMC article.
Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: a MASTER cohort study.
Quiros-Roldan E, Raffetti E, Castelli F, Focà E, Castelnuovo F, Di Pietro M, Gagliardini R, Gori A, Saracino A, Fornabaio C, Sighinolfi L, Di Filippo E, Maggiolo F, Donato F. Quiros-Roldan E, et al. Among authors: gagliardini r. J Antimicrob Chemother. 2016 Dec;71(12):3519-3527. doi: 10.1093/jac/dkw307. Epub 2016 Aug 19. J Antimicrob Chemother. 2016. PMID: 27543658
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial.
Lombardi F, Belmonti S, Quiros-Roldan E, Latini A, Castagna A, D'Ettorre G, Gagliardini R, Fabbiani M, Cauda R, De Luca A, Di Giambenedetto S; AtLaS-M Study Group. Lombardi F, et al. Among authors: gagliardini r. J Antimicrob Chemother. 2017 Jul 1;72(7):2055-2059. doi: 10.1093/jac/dkx068. J Antimicrob Chemother. 2017. PMID: 28333353 Clinical Trial.
3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir.
Gagliardini R, Bandera A, Zaccarelli M, Sterrantino G, Latini A, D'Avino A, Lapadula G, Antinori A, Cauda R, De Luca A, Gori A, Di Giambenedetto S, Fabbiani M. Gagliardini R, et al. Antivir Ther. 2018;23(2):139-148. doi: 10.3851/IMP3188. Antivir Ther. 2018. PMID: 28799920
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial.
Rossetti B, Gagliardini R, Meini G, Sterrantino G, Colangeli V, Re MC, Latini A, Colafigli M, Vignale F, Rusconi S, Micheli V, Di Biagio A, Orofino G, Ghisetti V, Fantauzzi A, Vullo V, Grima P, Francisci D, Mastroianni C, Antinori A, Trezzi M, Lisi L, Navarra P, Canovari B, D'Arminio Monforte A, Lamonica S, D'Avino A, Zazzi M, Di Giambenedetto S, De Luca A; for GUSTA trial study group. Rossetti B, et al. Among authors: gagliardini r. PLoS One. 2017 Nov 21;12(11):e0187393. doi: 10.1371/journal.pone.0187393. eCollection 2017. PLoS One. 2017. PMID: 29161288 Free PMC article. Clinical Trial.
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial.
Fabbiani M, Gagliardini R, Ciccarelli N, Quiros Roldan E, Latini A, d'Ettorre G, Antinori A, Castagna A, Orofino G, Francisci D, Chinello P, Madeddu G, Grima P, Rusconi S, Del Pin B, Lombardi F, D'Avino A, Focà E, Colafigli M, Cauda R, Di Giambenedetto S, De Luca A; ATLAS-M Study Group. Fabbiani M, et al. Among authors: gagliardini r. J Antimicrob Chemother. 2018 Jul 1;73(7):1955-1964. doi: 10.1093/jac/dky123. J Antimicrob Chemother. 2018. PMID: 29668978 Clinical Trial.
137 results